CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 23,378	$ 39,545
Short-term marketable securities	67,983	62,881
Receivables from collaborative arrangements	16,845	17,474
Prepaid clinical and development services	597	2,038
Other prepaid and current assets	7,677	11,603
Total current assets	116,480	133,541
Property and equipment, net	7,788	9,068
Operating lease assets	29,334	36,287
Future contingent milestone and royalty assets	194,200	194,200
Restricted cash	836	836
Other assets	7,467	8,067
Total assets	356,105	381,999
Current liabilities:
Accounts payable	1,454	1,524
Accrued personnel-related expenses	7,842	6,443
Accrued clinical and development expenses	864	2,246
Accrued general and administrative expenses	1,379	2,900
Operating lease liabilities	4,196	3,923
Tenant improvement payable to sublessee	6,490	6,490
Other accrued liabilities	1,210	1,241
Total current liabilities	23,435	24,767
Long-term operating lease liabilities	40,785	45,236
Future royalty payment contingency	29,691	27,788
Unrecognized tax benefits	71,563	65,294
Other long-term liabilities	4,977	5,919
Commitments and contingencies (Note 10)
Shareholders' Equity
Preferred shares, $0.00001 par value per share: 230 shares authorized, no shares issued or outstanding
Additional paid-in capital	1,135,599	1,122,164
Accumulated other comprehensive income (loss)	50	(65)
Accumulated deficit	(949,995)	(909,104)
Total shareholders' equity	185,654	212,995
Total liabilities and shareholders' equity	$ 356,105	$ 381,999